Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study ...
Introduction SLE is a chronic autoimmune disease characterised by multisystem involvement and fluctuating clinical course, ...
Active LN and the presence of U1-RNP antibodies were linked to low BMD and osteoporosis among patients with SLE.
Oral Presentation October 29, 2025, 11:20-11:29am PST MGFA Scientific Session Topline Results from MaGic, a Phase 2 Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia ...
The kit, in conjunction with Amperia's software and guided instructions, enables researchers to obtain antibody titre data.
Complement activation via the alternative pathway with subsequent generation of the C5a complement fragment has an important role in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated ...
--- The United States FDA Approves the Initiation for Phase II Efficacy Trial in Dermatomyositis (DM) Patients: A Skin & Muscle Disorder CLEVELAND, Feb. 24, 2025 (GLOBE NEWSWIRE) -- NovelMed ...
Complement activation may promote atherosclerosis. Yet, data on the to which extent complement, and more specifically the alternative complement pathway, is activated in patients with carotid ...